Evaluation of urinary and serum level of chemokine (C‐C motif) ligand 2 as a potential biomarker in canine urothelial tumours

Shimizu, Naomi; Hamaide, Annick; Dourcy, Mickaël; Noël, Stéphanie; Clercx, Cécile; Teske, Erik

doi:10.1111/vco.12436

Cited by 9 publications

(3 citation statements)

References 40 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found significantly higher concentrations of CCL2 in dogs affected with neoplasia than in healthy dogs. Other authors have observed significantly increased serum concentrations of CCL2 in dogs with pulmonary metastatic oral malignant melanoma (Maekawa et al 2022), urothelial carcinoma (Shimizu et al 2019), lymphoma (Perry et al 2011) and histiocytic sarcoma (Nielsen et al 2013). Allende et al (2020) reported an increased serum level of CCL2 in dogs with osteosarcoma; however, a significant difference was not found between the affected dogs and the healthy controls.…”

Section: Discussionmentioning

confidence: 92%

Plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases

Szczubiał,

Łopuszyński,

Dąbrowski

et al. 2023

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

The aim of this study was to evaluate the plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases. The concentrations of CCL2 and CXCL12 were determined in 25 female dogs with malignant mammary gland tumours (15 without metastases and 10 with metastases) and 10 healthy control animals using a specific canine ELISA assay. The mean plasma concentrations of CCL2 and CXCL12 were significantly higher (p<0.05) in the metastatic group compared to the control group. Moreover, the concentrations of these chemokines were markedly higher in the dogs with metastases than in those without metastases; however, a statistically significant difference was not found. The concentrations of both tested chemokines were numerically increased in the dogs with grade 2 and grade 3 carcinomas compared to the dogs with grade 1 carcinomas but the differences did not reach statistical significance. In conclusion, the results of our study demonstrate that plasma concentrations of chemokines CCL2 and CXCL12 are significantly increased in the dogs with metastatic malignant mammary gland tumours compared to the healthy dogs and show an upward trend compared to those without metastases. However, clarifying whether the increase of these chemokines is a cause or an effect of metastasis in female dogs with malignant mammary gland tumours as well as their potential role in metastatic process requires further research.

show abstract

Section: Discussionmentioning

confidence: 92%

Plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases

Szczubiał,

Łopuszyński,

Dąbrowski

et al. 2023

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

show abstract

“…A previous study has shown that urine CCL2 concentration as a diagnostic biomarker for urothelial carcinoma shows a sensitivity of 95% and specificity of 38%. 40 The simultaneous analysis of urine CCL17, which has a relatively high specificity, and CCL2, which has high sensitivity, may serve as a more accurate biomarker for urothelial carcinoma.…”

Section: Discussionmentioning

confidence: 99%

BRAF^V595E Mutation Associates CCL17 Expression and Regulatory T Cell Recruitment in Urothelial Carcinoma of Dogs

et al. 2020

View full text Add to dashboard Cite

Regulatory T cells may serve as targets in cancer immunotherapy. A previous study showed that the chemokine CCL17 and the receptor CCR4 play roles in regulatory T cell recruitment in canine urothelial carcinoma. In this article, we show that the BRAFV595E mutation is associated with tumor-produced CCL17 and regulatory T cell infiltration in dogs with urothelial carcinoma. In comparison with healthy dogs, dogs with urothelial carcinoma showed increased CCL17 mRNA expression in the bladder and elevated CCL17 protein concentration in urine. Immunohistochemistry showed increased levels of Foxp3+ regulatory T cells in the tumor tissues of urothelial carcinoma. The density of Foxp3+ regulatory T cells was positively correlated with CCL17 concentration in urine, indicating that CCL17 is involved in regulatory T cell recruitment. Moreover, tumor-infiltrating regulatory T cells and urine CCL17 concentration were associated with poor prognosis in dogs with urothelial carcinoma. The number of tumor-infiltrating regulatory T cells, CCL17 mRNA expression, and urine CCL17 concentration in cases with BRAFV595E mutation were higher than those in cases with wild-type BRAF. In vitro, high CCL17 production was detected in a canine urothelial carcinoma cell line with BRAFV595E mutation but not in an urothelial carcinoma cell line with wild-type BRAF. Dabrafenib, a BRAF inhibitor, decreased CCL17 production in the cell line with BRAFV595E mutation. These results suggest that BRAFV595E mutation induced CCL17 production and contributed to regulatory T cell recruitment in canine urothelial carcinoma.

show abstract

“…of dogs with urothelial carcinoma [133]. The combined measurement of CCL17 and CCL2 in urine might improve the sensitivity and specificity of each biomarker for detection of canine urothelial cancer [131].…”

Section: Diagnosismentioning

confidence: 99%

Diseases of the Canine Prostate Gland

Schäfer-Somi¹

2023

Recent Advances in Canine Medicine

View full text Add to dashboard Cite

In dogs, the most frequent diseases of the prostate gland are benign prostate gland hyperplasia (BPH), acute and chronic prostatitis, squamous metaplasia, and prostate tumors. New diagnostic tools comprise diagnostic markers in the blood and urine, as well as advanced imaging methods. The therapy can be initialized with the 5α-reductase-inhibitor finasteride or an anti-androgenic compound, and prolonged with a long-acting gonadotropin-releasing-hormone (GnRH)-agonist such as deslorelin. In case of prostatitis, effective antibiotics must be applied for weeks. Antibiotics must be able to penetrate into the prostate tissue; fluoroquinolones, clindamycin, and erythromycin are good choices and are in addition effective against mycoplasms. The chronical prostatitis cannot be differentiated from a neoplasia by sonography; a biopsy, histological, and bacteriological examination are required. Tumors of the prostate gland are seldom and mostly occur in castrated but in intact dogs. For the final diagnosis, a biopsy must be taken. Partial and total resection of the prostate gland by use of laser technique is possible but coincedes with many side effects and the prognosis is still futile. Immunotherapy combined with NSAIDs, targeted noninvasive thermotherapy, BRAF gene inhibitors, or prostate artery chemoembolization are promising methods.

show abstract

Evaluation of urinary and serum level of chemokine (C‐C motif) ligand 2 as a potential biomarker in canine urothelial tumours

Cited by 9 publications

References 40 publications

Plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases

Plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases

BRAF^V595E Mutation Associates CCL17 Expression and Regulatory T Cell Recruitment in Urothelial Carcinoma of Dogs

Diseases of the Canine Prostate Gland

Contact Info

Product

Resources

About

Evaluation of urinary and serum level of chemokine (C‐C motif) ligand 2 as a potential biomarker in canine urothelial tumours

Cited by 9 publications

References 40 publications

Plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases

Plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases

BRAFV595E Mutation Associates CCL17 Expression and Regulatory T Cell Recruitment in Urothelial Carcinoma of Dogs

Diseases of the Canine Prostate Gland

Contact Info

Product

Resources

About

BRAF^V595E Mutation Associates CCL17 Expression and Regulatory T Cell Recruitment in Urothelial Carcinoma of Dogs